US · IOVA
Iovance Biotherapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Carlos, CA 94070
- Website
- iovance.com
Price · as of 2025-12-31
$3.40
Market cap 1.28B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.55 | +769.12% |
| Intrinsic Value(DCF) | $1.52 | -55.29% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $115.00 | ||||
| 2012 | $6.00 | ||||
| 2013 | $8.70 | ||||
| 2014 | $13.12 | ||||
| 2015 | $5.05 | ||||
| 2016 | $7.65 | ||||
| 2017 | $19.10 | ||||
| 2018 | $9.86 | ||||
| 2019 | $38.85 | ||||
| 2020 | $34.69 | ||||
| 2021 | $13.18 | ||||
| 2022 | $6.21 | ||||
| 2023 | $15.70 | ||||
| 2024 | $3.75 | $2,067.99 | $0.00 | $0.00 | $0.00 |
| 2025 | $3.79 | $29.55 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Iovance Biotherapeutics, Inc.'s (IOVA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.55
- Current price
- $3.40
- AI upside
- +769.12%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.52
-55.29% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IOVA | Iovance Biotherapeutics, … | $3.40 | 1.28B | +769% | -55% | — | — | -3.46 | 1.94 | 5.14 | -3.10 | — | 3.23 | 97.23% | -153.08% | -148.38% | -55.50% | -89.67% | -42.88% | 0.07 | — | 3.20 | 2.74 | 0.32 | -1484.00% | 6060.00% | -764.00% | -24.83% | -2.19 | -75.14% | 0.00% | 0.00% | 4.22% | -2.74 | -3.29 | 4.20 | -1.24 |
| ATXS | Astria Therapeutics, Inc. | $12.58 | 718.13M | — | — | — | — | -3.69 | 1.09 | — | -0.26 | — | 1.09 | 0.00% | — | — | -33.52% | 3380.03% | -31.58% | 0.02 | — | 17.49 | 17.15 | 0.58 | -3058.00% | — | 1908.00% | -23.45% | -4.25 | 2470.44% | 0.00% | 0.00% | 0.00% | -0.22 | -0.30 | — | 6.30 |
| AVBP | ArriVent BioPharma, Inc. … | $22.97 | 948.23M | — | — | — | — | -8.55 | 2.67 | — | -5.83 | -47.58 | 2.67 | 0.00% | — | — | -39.36% | -469.29% | -36.75% | 0.00 | — | 13.14 | 12.70 | 0.92 | 1797.00% | — | 2573.00% | -10.20% | -4.06 | -349.38% | 0.00% | 0.00% | 0.00% | -4.98 | -6.69 | — | 22.46 |
| CTMX | CytomX Therapeutics, Inc. | $5.37 | 909.87M | +2,414% | -87% | -65% | +202% | 1.76 | -123.14 | 0.41 | -1.31 | — | -28.25 | 100.00% | 18.10% | 23.08% | -133.06% | -16.56% | 19.77% | -20.58 | — | 1.25 | 1.21 | -1.07 | -503506.00% | 3645.00% | 5216.00% | -154.12% | -1.01 | 57.76% | 0.00% | 0.00% | 45.36% | -1.40 | 0.41 | -0.25 | -5.71 |
| DNA | Ginkgo Bioworks Holdings,… | $6.75 | 408.98M | +75% | -49% | — | +1,219% | -1.25 | 0.77 | 2.30 | -1.51 | — | 0.87 | 81.48% | -185.29% | -183.81% | -51.08% | -55.89% | -25.05% | 0.82 | — | 4.92 | 4.65 | -0.98 | -4649.00% | -2506.00% | -5323.00% | -45.71% | -1.78 | -31.77% | 0.00% | 0.00% | 0.00% | -1.22 | -2.16 | 2.27 | -7.68 |
| ERAS | Erasca, Inc. | $13.66 | 4.23B | — | — | — | — | -2.21 | 0.84 | — | -0.73 | — | 0.84 | 0.00% | — | — | -43.68% | -151.38% | -36.01% | 0.12 | — | 9.84 | 9.58 | 0.10 | -1687.00% | — | 2814.00% | -36.89% | -3.49 | -111.24% | 0.00% | 0.00% | 0.00% | -0.62 | -0.84 | — | 0.06 |
| MBX | MBX Biosciences, Inc. Com… | $32.55 | 1.09B | — | — | — | — | -5.33 | 1.28 | — | -1.00 | -6.55 | 1.28 | 0.00% | — | — | -66.95% | 86.67% | -35.11% | 0.00 | — | 24.19 | 23.78 | 0.72 | 8137.00% | — | 7303.00% | -16.82% | -4.95 | 70.61% | 0.00% | 0.00% | 5.75% | -1.00 | -1.23 | — | 17.45 |
| MGTX | MeiraGTx Holdings plc | $7.56 | 608.51M | +360% | -66% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| MLTX | MoonLake Immunotherapeuti… | $17.51 | 1.24B | — | — | — | — | -4.97 | 3.74 | — | -3.74 | -5.73 | 3.74 | 0.00% | — | — | -60.99% | 4029.60% | -50.78% | 0.25 | -33.78 | 9.27 | 8.77 | 1.18 | 8677.00% | — | 6740.00% | -17.20% | -4.31 | 3226.55% | 0.00% | 0.00% | 7.13% | -3.36 | -4.19 | — | 3.33 |
| REPL | Replimune Group, Inc. | $7.65 | 631.68M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
- CEO
- Frederick G. Vogt
- Employees
- 838
- Beta
- 0.78
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.52 ÷ $3.40) − 1 = -55.29% (DCF, example).